Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031700 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KDM4EOPRM1CACNA2D1TP53 | |
| SCHEMBL2878269 | 0.89 | ALDH1A1 (0.45) | ALDH1A1OPRM1CACNA2D1MEN1KMT2A | |
| SCHEMBL2878267 | 0.89 | ALDH1A1 (0.45) | ALDH1A1OPRM1CACNA2D1MEN1KMT2A | |
| SCHEMBL14048965 | 0.79 | OPRM1 (0.36) | ALDH1A1OPRM1CACNA2D1POLB | |
| SCHEMBL2431376 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL2431371 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL989690 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL2107036 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL6830100 | 0.76 | ALDH1A1 (0.40) | ALDH1A1KDM4EOPRM1CACNA2D1TP53 | |
| SCHEMBL2880725 | 0.75 | SMN1; SMN2 (0.48) | ALDH1A1OPRM1MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | ALDH1A1 1591/4885KDM4E 1505/4885OPRM1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.